Using a single test assessing hundreds of current and emerging cancer biomarkers, you can now access a clinically relevant report with actionable answers.
Learn MoreThe MiSeqDx instrument is the first FDA-cleared <i>in vitro</i> diagnostic (IVD) next-generation sequencing (NGS) system.
MiSeqDx applications include FDA-cleared and FDA-approved assays for cystic fibrosis testing, colorectal cancer evaluation, and NGS-based assay development.
FDA-cleared next-generation sequencing panels for detection of causative and clinically relevant variants for cystic fibrosis.